LYNAVOY

This brand name is authorized in United States. It is also authorized in Lithuania.

Active ingredients

The drug LYNAVOY contains one active pharmaceutical ingredient (API):

`1`	Linerixibat UNII `386012Z45S` - LINERIXIBAT
	Linerixibat is a locally acting, minimally absorbed reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids in the ileum leading to increased faecal elimination. Linerixibat improves pruritus in PBC patients which is assumed to be due to a decrease in mediators of pruritus including serum bile acids, lysophosphatidic acid (LPA) [via measurement of autotaxin as a surrogate] and interleukin 31 (IL-31).
	Read more about Linerixibat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYNAVOY Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
LYNAVOY Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
LT	Valstybinė vaistų kontrolės tarnyba	1108758, 1108759, 1108760
US	FDA, National Drug Code	0173-0938

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.